Cargando…
Twenty-five years in the making: flecainide is safe and effective for the management of atrial fibrillation
Atrial fibrillation (AF) is the most common arrhythmia in clinical practise and its prevalence is increasing. Over the last 25 years, flecainide has been used extensively worldwide, and its capacity to reduce AF symptoms and provide long-term restoration of sinus rhythm (SR) has been well documented...
Autores principales: | , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3024037/ https://www.ncbi.nlm.nih.gov/pubmed/21138930 http://dx.doi.org/10.1093/europace/euq382 |
_version_ | 1782196730647805952 |
---|---|
author | Aliot, Etienne Capucci, Alessandro Crijns, Harry J. Goette, Andreas Tamargo, Juan |
author_facet | Aliot, Etienne Capucci, Alessandro Crijns, Harry J. Goette, Andreas Tamargo, Juan |
author_sort | Aliot, Etienne |
collection | PubMed |
description | Atrial fibrillation (AF) is the most common arrhythmia in clinical practise and its prevalence is increasing. Over the last 25 years, flecainide has been used extensively worldwide, and its capacity to reduce AF symptoms and provide long-term restoration of sinus rhythm (SR) has been well documented. The increased mortality seen in patients treated with flecainide in the Cardiac Arrhythmia Suppression Trial (CAST) study, published in 1991, still deters many clinicians from using flecainide, denying many new AF patients a valuable treatment option. There is now a body of evidence that clearly demonstrates that flecainide has a favourable safety profile in AF patients without significant left ventricular disease or coronary heart disease. As a result of this evidence, flecainide is now recommended as one of the first-line treatment options for restoring and maintaining SR in patients with AF under current treatment guidelines. The objective of this article is to review the literature pertaining to the pharmacological characteristics, safety and efficacy of flecainide, and to place this drug in the context of current therapeutic management strategies for AF. |
format | Text |
id | pubmed-3024037 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2011 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-30240372011-01-21 Twenty-five years in the making: flecainide is safe and effective for the management of atrial fibrillation Aliot, Etienne Capucci, Alessandro Crijns, Harry J. Goette, Andreas Tamargo, Juan Europace Review Atrial fibrillation (AF) is the most common arrhythmia in clinical practise and its prevalence is increasing. Over the last 25 years, flecainide has been used extensively worldwide, and its capacity to reduce AF symptoms and provide long-term restoration of sinus rhythm (SR) has been well documented. The increased mortality seen in patients treated with flecainide in the Cardiac Arrhythmia Suppression Trial (CAST) study, published in 1991, still deters many clinicians from using flecainide, denying many new AF patients a valuable treatment option. There is now a body of evidence that clearly demonstrates that flecainide has a favourable safety profile in AF patients without significant left ventricular disease or coronary heart disease. As a result of this evidence, flecainide is now recommended as one of the first-line treatment options for restoring and maintaining SR in patients with AF under current treatment guidelines. The objective of this article is to review the literature pertaining to the pharmacological characteristics, safety and efficacy of flecainide, and to place this drug in the context of current therapeutic management strategies for AF. Oxford University Press 2011-02 2010-12-07 /pmc/articles/PMC3024037/ /pubmed/21138930 http://dx.doi.org/10.1093/europace/euq382 Text en Published on behalf of the European Society of Cardiology. All rights reserved. © The Author 2010. For permissions please email: journals.permissions@oxfordjournals.org http://creativecommons.org/licenses/by-nc/2.5/ The online version of this article has been published under an open access model. Users are entitled to use, reproduce, disseminate, or display the open access version of this article for non-commercial purposes provided that the original authorship is properly and fully attributed; the Journal, Learned Society and Oxford University Press are attributed as the original place of publication with correct citation details given; if an article is subsequently reproduced or disseminated not in its entirety but only in part or as a derivative work this must be clearly indicated. For commercial re-use, please contact journals.permissions@oxfordjournals.org. |
spellingShingle | Review Aliot, Etienne Capucci, Alessandro Crijns, Harry J. Goette, Andreas Tamargo, Juan Twenty-five years in the making: flecainide is safe and effective for the management of atrial fibrillation |
title | Twenty-five years in the making: flecainide is safe and effective for the management of atrial fibrillation |
title_full | Twenty-five years in the making: flecainide is safe and effective for the management of atrial fibrillation |
title_fullStr | Twenty-five years in the making: flecainide is safe and effective for the management of atrial fibrillation |
title_full_unstemmed | Twenty-five years in the making: flecainide is safe and effective for the management of atrial fibrillation |
title_short | Twenty-five years in the making: flecainide is safe and effective for the management of atrial fibrillation |
title_sort | twenty-five years in the making: flecainide is safe and effective for the management of atrial fibrillation |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3024037/ https://www.ncbi.nlm.nih.gov/pubmed/21138930 http://dx.doi.org/10.1093/europace/euq382 |
work_keys_str_mv | AT aliotetienne twentyfiveyearsinthemakingflecainideissafeandeffectiveforthemanagementofatrialfibrillation AT capuccialessandro twentyfiveyearsinthemakingflecainideissafeandeffectiveforthemanagementofatrialfibrillation AT crijnsharryj twentyfiveyearsinthemakingflecainideissafeandeffectiveforthemanagementofatrialfibrillation AT goetteandreas twentyfiveyearsinthemakingflecainideissafeandeffectiveforthemanagementofatrialfibrillation AT tamargojuan twentyfiveyearsinthemakingflecainideissafeandeffectiveforthemanagementofatrialfibrillation |